Nicolas Chapuis et al. found that IGF-1 spontaneous lesions played a key role in PI3K/AKT activation of AML cells, providing strong evidence for targeting IGF1R as a potential new therapy for AML (37). The gene discussed is IGF1R; the disease is acute myeloid leukemia.